Skip to Content
Morningstar

Intellia Therapeutics Inc NTLA

Morningstar Rating
Unlock
Stock XNAS Rating as of
$26.26 +0.52 (2.02%)
View Full Chart
As of Cboe BZX Real-Time Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Intellia Earnings: Novel Gene Editing Pipeline Advances; Shares Attractive for Long-Term Investors

Rachel Elfman

Intellia Therapeutics’ relatively early-stage gene editing pipeline continued to make progress in the first quarter. We have raised our estimated probability of approval for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy and polyneuropathy to 40% from 30% as the company has quickly enrolled patients in its phase 3 trial for ATTR amyloidosis with cardiomyopathy, and it is tracking ahead of projections. We anticipate research and development costs as a percentage of sales will remain elevated over the next few years as Intellia focuses on developing its pipeline candidates.

Read Full Report

Price vs Fair Value

View History
NTLA is trading at a 223% premium.
Price
$25.73
Fair Value
$73.00
Uncertainty
Very High
1-Star Price
$762.53
5-Star Price
$13.10
Economic Moat
Gwbq
Capital Allocation
Lzdgnnq

Bulls Say, Bears Say

Bulls

Intellia's partnerships allow it to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

Bears

Intellia's pipeline is largely in the early stages of development and several years away from potentially receiving approval.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NTLA is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$25.74
Day Range
$26.06–27.14
52-Week Range
$19.40–47.48
Bid/Ask
$26.24 / $26.28
Market Cap
$2.54 Bil
Volume/Avg
470,307 / 1.5 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
42.81
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
598
Website
https://www.intelliatx.com

Competitors

Valuation

View More
Metric
NTLA
CRSP
BNTX
Price/Earnings (Normalized)
 ——29.10
Price/Book Value
 2.392.271.02
Price/Sales
 42.8116.517.53
Price/Cash Flow
 ———
Price/Earnings
NTLA
CRSP
BNTX

Financial Strength

Metric
NTLA
CRSP
BNTX
Quick Ratio
 8.4517.7210.95
Current Ratio
 9.0317.8111.38
Interest Coverage
 ———
Quick Ratio
NTLA
CRSP
BNTX

Profitability

Metric
NTLA
CRSP
BNTX
Return on Assets (Normalized)
 −26.32%−6.45%−0.14%
Return on Equity (Normalized)
 −31.79%−7.71%−0.15%
Return on Invested Capital (Normalized)
 −32.85%−6.83%−2.21%
Return on Assets
NTLA
CRSP
BNTX
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRKkcpjdgrmPpvf$586.5 Bil
VRTX
Vertex Pharmaceuticals IncJrbphlxdgSgpnrdf$110.6 Bil
REGN
Regeneron Pharmaceuticals IncPzxkprpRglxjgq$107.6 Bil
MRNA
Moderna IncQnnjrthrnQgwps$48.2 Bil
BNTX
BioNTech SE ADRFtqkdhvqHbvm$22.2 Bil
ARGX
argenx SE ADRNwsxvnzwYtgr$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncCnztkktxXplmj$19.0 Bil
BMRN
Biomarin Pharmaceutical IncKcntwjfmMyjyf$15.1 Bil
INCY
Incyte CorpNrnnvsnrQxfnz$12.8 Bil
RPRX
Royalty Pharma PLC Class ADmtvkhxfhWvmwgsk$12.7 Bil

Sponsor Center